Given that some cancer cells are resistant to GPX4-inhibition-induced ferroptosis, and that FSP1 inhibitors sensitize a number of cancer cells to ferroptosis induced by sublethal GPX4 inhibition, the combination therapy of FSP1 inhibitors with canonical ferroptosis inducers, such as GPX4 and system xc− inhibitors, ideally in a tumor-specific manner, could potentially be a new anticancer therapy. This evidence concerns the gene GPX4 and neoplasm.